María-Victoria Mateos

María-Victoria Mateos, MD, PhD is Head of the Hematology Department and Principal Investigator of the Myeloma Program at Hospital Universitario de Salamanca and a professor of hematology at the University of Salamanca. She is one of Europe's most prominent myeloma clinical investigators, best known for her leadership of the MAIA trial — one of the most impactful myeloma studies of the last decade. The MAIA trial (NEJM 2019) demonstrated that daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved PFS and overall survival compared with lenalidomide/dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma — establishing D-Rd as a global standard of care for this population and leading to FDA approval. Dr. Mateos has been a longstanding collaborator of Jesús San Miguel and a key member of the Spanish GEM (Grupo Español de Mieloma) cooperative group, contributing to landmark trials of VMP, VTd, and novel combinations in both transplant-eligible and transplant-ineligible patients. She has taken particular interest in frailty-adapted therapy for elderly myeloma patients and led GEM studies defining attenuated regimens appropriate for unfit patients. Dr. Mateos has authored over 350 peer-reviewed publications and is a frequent invited speaker at ASH, EHA, and IMWG congresses.